Effect of zoledronic acid on osteoarthritis of the hip

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2019-000757-31-NO

Enrollment

Registered

2019-02-14

Start date

2019-08-30

Completion date

Unknown

Last updated

2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Investigated disease is osteoarthritis of the hip with concurrent Bone marrow lesions

Interventions

Trade Name: Zoledronic Acid (Fresenius Kabi) Product Name: Zoledronic Acid Pharmaceutical Form: Infusion Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenou

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hip Osteoarthritis. Bone marrow lesion > 1 cm. Age 50-80. pain VAS >4 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 35 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 35

Exclusion criteria

Exclusion criteria: kidney failure GFR 80. Prosthesis on contralateral hip or ipsilateral knee. calcium or vitamin d deficiency. Use of other bone modulating medication

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the effect on pain, functional improvement and quality of life. To investigate bone quality with microindentation and cartilage degredation after treatment;Secondary Objective: To investigate the effect on pain, functional improvement and quality of life. To investigate bone quality with microindentation and histochemical analysis and cartilage degredation after treatment;Primary end point(s): Visual analog scale;Timepoint(s) of evaluation of this end point: 12 months	—

Measure

Time frame

Main Objective: To investigate the effect on pain, functional improvement and quality of life. To investigate bone quality with microindentation and cartilage degredation after treatment;Secondary Objective: To investigate the effect on pain, functional improvement and quality of life. To investigate bone quality with microindentation and histochemical analysis and cartilage degredation after treatment;Primary end point(s): Visual analog scale;Timepoint(s) of evaluation of this end point: 12 months

—

Secondary

Measure	Time frame
Secondary end point(s): HOOS score. Harris Hip Score EQ-5D Microindentation score cartilage thickness on MRI use of analgetics change in bone turnover;Timepoint(s) of evaluation of this end point: 12 months	—

Countries

Norway

Contacts

Public ContactMehran Karimzadeh

South east health region of Norway

mehran.karimzadeh@mhh.no+4741430288

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026